Category Archives: Company News

Kineticos to Attend BIO 2017

Kineticos will be in San Diego, CA the week of June 19th attending BIO 2017.  We’d love to meet with biotech leaders seeking in- and out-licensing opportunities.  Kineticos has a methodical and proven approach to helping companies secure partnering meetings with interested pharmaceutical companies.

To learn more or to schedule a meeting at BIO, contact Kevin Hampton.


Kineticos is a specialized management consulting firm serving the life science
industry.

At Kineticos, we have a simple mission: to help our sponsors solve their most complex problems. We work exclusively within the life sciences ecosystem. And our focus is strategy, business development & licensing, market access, innovation and operational excellence. Our values start with an entrepreneurial culture focused on exceptional outcomes for our sponsors through deep engagements. We foster an environment where our business and life science experts can be creative, critical and collaborative thinkers. We value context and transparency over hierarchy and control. We do all of this to improve patient outcomes, our shared purpose with our sponsors.

For more information on Kineticos and its capabilities, please visit www.kineticos.com.

Kineticos to Sponsor February 27th Life Science Forum

Kineticos is serving as a lead sponsors for the upcoming Life Sciences Forum on February 27th at the NC Biotech Center in the heart of Research Triangle Park.  We invite you to join us along with other local industry leaders to discuss Value Based Medicine: The Collision of Innovation and Affordability.  See below for more details and click here to register.


Value Based Medicine: The Collision of Innovation and Affordability

Unprecedented advances in medical innovation are expanding life expectancy, improving quality of life, and even providing cures for life-threatening diseases. Yet the cost associated with this innovation now lies at the center of the national dialogue over cost, affordability, and access in health care.

Moderator

  • Susan Cantrell – Chief Executive Officer, Academy of Managed Care Pharma

Panelists

  • Jane Reese-Coulbourne, M.S., ChE – Senior Consultant, Mark Krueger & Associates
  • Janet McCauley, M.H.A., M.D. – Senior Medical Director, Blue Cross Blue Shield of North Carolina
  • Chris Little, PharmD, BCPS – Director, Pharmacy & Diagnostic Imaging, Resource Optimization & Innovation

Agenda

  • 4pm – Registration
  • 4:30pm – Panel Session
  • 6pm – Networking

To view full details of the event, click here

Kineticos to Sponsor the Q4 Life Science Forum

Kineticos is sponsoring the Q4 Life Sciences Forum on December 6th at the NC Biotech Center.  We invite you to join us along with other local industry leaders to discuss how Covis Pharma went from startup to a billion dollar exit.  See below for more details and click here to register.


From Startup to a Billion Dollar Exit – “The Covis Story”

What is the current and future landscape of the pharmaceutical and specialty pharma industry?  How can a start-up company navigate the legal, regulatory, cross-border structuring, life-cycle management and licensing challenges to build a billion dollar company?

Come hear relevant insights regarding the merger and financing environment, industry trends and developments, and how a company achieved worldwide sales growth through license agreements and efficient structuring that ultimately led to a billion dollar exit.

Panelists

  • Jack Davis – Former Chief Executive Officer, Covis Pharma
  • Sean King – President and Managing Director, Align Global Consulting
  • Banks Bourne – Chief Executive Officer/Sr. Managing Director, Bourne Partners

Moderator

  • Tim Gupton – Partner & Financial Advisor, HPG Wealthcare Advisors, LLC

Agenda

  • 4pm – Registration
  • 4:30pm – Panel Session
  • 6pm – Networking

To view full details of the event, click here

Kineticos Expands Biopharmaceutical Practice Leadership Team, Bolsters Oncology Focus with Senior Vice President Appointment

Consulting Firm Hires Senior Leader Within Biopharmaceutical Practice – 

October 28, 2016 – Raleigh-Durham, N.C. – Kineticos, a specialized strategy consulting firm serving the life sciences industry, today announced the expansion of its Biopharmaceutical practice leadership team with the addition of Glen Martin, Senior Vice President.

Glen Martin joins Kineticos as a seasoned executive with more than 22 years of experience in the biopharmaceutical industry. Mr. Martin held roles in sales for several start up biopharma companies before moving to Pharmion, a then-leading global oncology company. While at Pharmion, Mr. Martin held various management roles in sales before moving to Medical Affairs and becoming the National Director of the US Medical Science Liaison program. After Pharmion was acquired by Celgene in 2008, Glen took on responsibilities as Celgene’s Senior Director, Outcomes Research & Operations. Subsequently, Glen spent 4 years serving in the capacity of Chief of Staff for Celgene’s US Medical Affairs group before being recruited by Covis Pharma, a unique start up company, to serve as Vice President of Oncology Sales. Following the acquisition of Covis, Mr. Martin served as Senior Vice President, Medical Sciences for Ashfield Healthcare. Mr. Martin earned his BA in Psychology from LaSalle University in Philadelphia, PA.

“Glen adds extensive cross-functional experience to the practice along with an impressive track record of bringing new biopharmaceutical products to market with a focus on oncology,” stated Founder and CEO of Kineticos, Shailesh Maingi. “Our clients are the heart of our entrepreneurial consulting practice. Glen’s expertise adds depth to our existing consulting capabilities, especially in oncology which constitutes 40% of all active clinical trials, and adds more resources to our practice as an increasing number of biopharma clients depend on our team to guide their path to market,” he continued.

About the Biopharmaceutical Practice at Kineticos

The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels. The firm’s consulting team members have a depth of expertise across functional areas and therapeutic areas, established through decades of work in consulting and in industry. Overall, the practice has a strong commitment to client satisfaction and a proven ability to deliver results through practical solutions. The Biopharmaceutical practice at Kineticos supports clients across three service areas including corporate strategy & development, medical affairs strategy and commercial strategy. For more information on the Biopharmaceutical practice at Kineticos, please visit http://www.kineticos.com/life-science-consulting-companies/biopharmaceutical-practice/. 

About Kineticos

Kineticos is a specialized strategy consulting firm serving the life science industry.

At Kineticos, we have a simple mission: to help our sponsors solve their most complex problems. We work exclusively within the life sciences ecosystem. And our focus is strategy, business development & licensing, market access, innovation and operational excellence. Our values start with an entrepreneurial culture focused on exceptional outcomes for our sponsors through deep engagements. We foster an environment where our business and life science experts can be creative, critical and collaborative thinkers. We value context and transparency over hierarchy and control. We do all of this to improve patient outcomes, our shared purpose with our sponsors.

Kineticos to Sponsor Life Science Forum

Kineticos is sponsoring the Life Sciences Forum on October 25th at the NC Biotech Center.  We invite you to join us along with other local industry leaders to discuss “The Sizzling Science and Business of Immuno-Oncology”.  Details are below and to register, click here

The Sizzling Science and Business of Immuno-Oncology

What is the immuno-oncology revolution that’s sweeping the world of cancer treatments? How is it impacting every aspect of cancer treatment development for companies (small and large), clinicians, payers and patients?

Come hear from panelists who are living at the pioneering intersection of science and business of immuno-oncology. Ask your tough questions about the field and its potential to provide cures to certain cancers.

Panelists

  • Mark Velleca, MD, PhD – Chief Executive Officer, G1 Therapeutics
  • Smita Nair, PhD – Associate Professor of Surgery, Duke University School of Medicine and Director of Immunotherapy Sciences Focus Group, Duke Cancer Institute
  • Taylor Schreiber, MD, Ph. – Chief Scientific Officer, Heat Biologics
  • Bruce McCreedy, PhD – Senior Vice President Cell Therapy, Precision BioSciences

Agenda

  • 4pm – Registration
  • 4:30pm – Welcome
  • 6pm – Networking

To view full details of the event, click here

Tickets are $25 advance/$30 on-site.  Click here to Register

Kineticos and Cardinal Health Regulatory Sciences to host a live webinar – “Achieving Success in the Biosimilars Market”

Kineticos is pleased to announce that on Wednesday, October 19th, it will be cohosting its first live webinar with Cardinal Health Regulatory Sciences. See below for more details and to register, click here.

Event Overview

Less than one year after the first biosimilar launched in the U.S., analysts are reporting that the worldwide biosimilar market is expected to reach $35 Billion by 2020, according to Allied Market Resource. This new approval pathway for biopharmaceutical companies has significant implications on the market landscape, creating opportunities and challenges. In this webcast, regulatory affairs, product development and commercialization consulting experts from Cardinal Health Regulatory Sciences and Kineticos will discuss the potential impact of biosimilars on product portfolios and competition. Additionally, they will share insights on navigating this evolving landscape to develop a successful strategy to optimize success.

Presenters

  • Mark Osterman – Senior Vice President, Kineticos
  • Trey Putnam, PhD, RAC – Vice President and General Manager, Cardinal Health Regulatory Sciences

Upon completion of this webcast, attendees will be able to:

  1. Make more informed decisions in regard to successful biosimilar launches
  2. Better navigate the regulatory aspects of the biosimilar development and approval processes
  3. Understand market access success factors

Who Should Attend:

  1. Biopharmaceutical C-suite, VPs, Directors and Product Managers
  2. Therapeutic VPs and Directors
  3. Clinical Development C-suite, VPs, Directors and Manager

CLICK HERE TO REGISTER FOR THIS FREE EVENT


 

Kineticos Featured in Ivy Exec’s Company Spotlight Series

Kineticos was recently featured in Ivy Exec’s 2016 Company Spotlight Series, which highlights leading Life Sciences/Healthcare consulting firms that are in a position of growth.   Ivy Exec, founded in 2006, runs an online professional network for executives as well as an online recruitment firm.  Kineticos is continuously seeking out talented professionals to join our team and with over 130,000 of Ivy Exec’s 670,000 active members working in management consulting, this was a chance to showcase our entrepreneurial culture and dedication to solving our clients’ most complex challenges.

The article, which was written following an interview with Kineticos CEO, Shailesh Maingi, offers insight into what makes Kineticos stand out in a competitive hiring market.

To view the article, click here

 

Kineticos to Sponsor the Q2 Life Sciences Forum on May 23rd at the NC Biotech Center

Kineticos is sponsoring the Q2 Life Sciences Forum on May 23rd at the NC Biotech Center.  The Q1 forum drew an audience of over 150 life science industry leaders and we look to carry that success into the Q2 forum as we build a stronger community along the way.  Kineticos invites you to join us along with other local industry leaders to discuss Transforming University Innovations on Monday, May 23rd to at the NC Biotech Center.  Details are below.

Transforming University Innovations

A panel of innovation leaders from four of North Carolina’s leading research institutions will provide an overview of several exciting initiatives each is undertaking to foster and create life sciences innovation that will lead to our region’s next great technologies and companies.

These universities are taking fresh approaches with significant support and are revitalizing university technology commercialization.  This panel will be of interest to entrepreneurs, executives at established companies and investors.

Panelists

  • Eric Tomlinson, DSc, Ph.D – Chief Innovation Officer, Wake Forest Innovations
  • Judith Cone – Vice Chancellor, Commercialization and Economic Development, UNC – Chapel Hill
  • Barry Myers, M.D., Ph.D., MBA – Professor, Department of Biomedical Engineering, Duke University
  • Kelly Sexton, Ph.D. – Director, Office of Technology Transfer, NC State University

Agenda

  • 4pm – Registration
  • 4:30pm – Welcome
  • 6pm – Networking

To view full details of the event, click here

Tickets are $25 advance/$30 on-site.  Click here to Register

Confidence Wanes as Uncertainty Builds in the Q4 2015 Biopharma CEO Confidence Index

Feb. 19, 2016 – Raleigh-Durham, NC — Kineticos, in partnership with Ipsos Healthcare and Demy-Colton Life Science Advisors, today announced the Q4 2015 results of the Biopharma CEO Confidence Index, a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s economy.

This confidence—or lack thereof—is defined by the degree of optimism within six key business indicators. In summary, 54 CEOs of US-based biopharmaceutical companies expressed more uncertainty in Q4 2015 compared to Q3 2015 in relation to capital markets and deal landscape while the other four areas, clinical development, regulatory affairs, commercialization, and business model and workforce, remained stable.

Here are a few highlights from the Q4 Biopharma CEO Confidence Index:

  • CEOs who were very confident in their ability to raise capital in the next 18 months declined from 53% in Q3 to 39% in Q4
  • CEOs who viewed the current deal landscape as good declined from 82% in Q3 to 61% in Q4
  • CEOs who were very confident in their ability to deliver therapies in 3-5 years remained stable in Q4 at 91% compared to 86% in Q3
  • Oncology (37%) and Neurology (33%) remain the focus of licensing transactions
  • 33% of CEOs believed transaction values were increasing in Q4, compared to 59% in Q3
  • Three out of four CEOs outsource the majority of their clinical development functions

A more extensive summary of the Q4 2015 Biopharma CEO Confidence Index is available at www.BiopharmaCEOConfidenceIndex.com.

When asked about the results of the Q4 index, executives from all three partner organizations shared a similar sentiment.

Steve Girling, President of Ipsos Healthcare, offered his commentary when asked if the Q4 results were in line with his expectations. “It’s too early to call this slip in CEO confidence a trend, but as we know from the last significant market contraction in 2009, development stage company fortunes are inextricably tied to the cycle of the global financial markets. It will be fascinating to see the next wave of results!”

Sara Demy of Demy-Colton Life Science Advisors made a similar observation: “As a conference organizer focusing exclusively in biopharmaceuticals and life sciences, we engage with this audience daily. The Q4 results are completely aligned with 1-1 conversations I’ve personally had with several biotech CEOs.”

Shailesh Maingi, CEO and Founder of Kineticos, also made comments on the broader picture: “CEOs, particularly ones that manage emerging biopharmaceutical companies, must have a long term perspective. The therapies being developed today for oncology, CNS, and immunology diseases reflect the promise of immuno-oncology, gene/cell therapy, pharmacogenomics, and other new technologies. Our confidence index reflects the optimism that biopharma CEOs have over the longer term, albeit at a level lower than a few months ago.”

About the Biopharma CEO Confidence Index

The Biopharma CEO Confidence Index, is the first and only forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s economy. This confidence—or lack thereof—is defined by the degree of optimism within six key business indicators, including:

  1. Capital Markets
  2. Deal Landscape
  3. Clinical Development
  4. Regulatory Affairs
  5. Commercialization
  6. Business Model and Workforce

Measuring confidence through these indicators over time will demonstrate an ebb and flow of market dynamics and confidence in the future success of companies and growth in the overall market.

About Kineticos

Kineticos is a specialized management consulting firm serving the life science industry.

The firm is focused on identifying opportunities to drive strategic growth and achieve operational excellence for its clients in the US, Europe, and Asia. Through its practice areas, the firm has experience working with companies across the life science industry ecosystem. For more information on Kineticos and its capabilities, please visit www.kineticos.com.

About Ipsos Healthcare

Ipsos Healthcare is a fact-based research, consulting and strategy specialist in the global biopharmaceutical industry. For more information, please visit www.ipsos.com/marketing/healthcare.

About Demy-Colton Life Science Advisors

Demy-Colton Life Science Advisors produces highly specialized investor and business conferences exclusively for the biopharmaceutical and life sciences industry. For more information, please visit www.demy-colton.com.

Kineticos to Sponsor Life Sciences Forum on February 29th at the NC Biotech Center

Kineticos has agreed to be a lead sponsor at the Life Sciences Forum on February 29th at the NC Biotech Center.  Join Kineticos along with other life science industry leaders on Monday, February 29, to build a stronger community and drive innovation at the inaugural quarterly Life Sciences Forum.

Venture Philanthropy Panel

The funding landscape has changed to include a greater role for venture philanthropy in life science product development. This interactive panel will discuss the benefits of including venture philanthropy in a company’s financing plan, how to approach these groups for funding, and how venture philanthropies are changing their models to maximize impact.

Panelist

Moderator

Agenda:

  • 4 p.m. – Registration
  • 4:30 p.m. – Program
  • 6 p.m. – Reception and networking

To view full details of the event, click here

Tickets are $25 advance/$30 on-site.  Click here to Register

About Kineticos

Kineticos is a specialized management consulting firm serving the life science industry. The firm is focused on identifying opportunities to drive strategic growth and achieve operational excellence for its clients. Kineticos’ capabilities reside in six core service areas: Strategy and Growth, R&D Innovation, Operational Excellence, Sales and Go-to-Market, M&A, and Strategic Sourcing. The firm maintains a broad base of clients including biopharmaceutical companies, services companies, and investors. To learn more, visit the company’s website at http://www.kineticos.com.

Contact: Kevin Hampton – kevin.hampton@kineticos.com